The National Health and Health Commission issued a number of large varieties will be focused on supervision.

Medical Network August 3, July 29, the National Health and Care Commission issued "on the clinical application of anti-tumor drugs for the management of public consultation" (hereinafter referred to as the "Measures"), anti-tumor drug clinical use of specific requirements. According to
the announcement, the Measures refer to anti-tumor drugs referred to in the Measures, through cell killing, immune regulation, endocrine regulation and other means, in the cellular, molecular level to act to inhibit tumor growth or eliminate tumor drugs, generally including chemotherapy drugs, molecular-targeted drugs, endocrine therapy drugs, immunotherapy drugs.
the Measures require the clinical application of anti-tumor drugs to implement hierarchical management.
according to safety, accessibility, economy and other factors, anti-tumor drugs are divided into restricted use and general use level.
specific classification criteria are as follows: (1) restricted use of grade anti-tumor drugs refers to anti-tumor drugs with one of the following characteristics: 1. Drug toxic side effects, including toxic drugs management, strict adaptation certificate, taboo evidence, must be used by medical personnel with rich clinical experience, improper use may cause serious damage to the human body anti-tumor drugs;
(ii) General use of grade anti-tumor drugs refers to other anti-tumor drugs other than restricted use of anti-tumor drugs.
In addition, the Measures require medical institutions to establish a system for the selection and evaluation of anti-tumor drugs, to develop a catalogue of anti-tumor drugs according to the needs of their cancer disease diagnosis and treatment, and to adjust them regularly. The selection of anti-tumor drug varieties in
medical institutions should be based on clinical needs, giving priority to the selection of the national list of essential drugs, the national basic medical insurance drug catalogue, the centralized negotiation or tender procurement, and the national health and wellness announced by the norms of diagnosis and treatment, clinical diagnosis and treatment guidelines, clinical path recommended varieties.
can be seen, for the relevant pharmaceutical companies, in addition to health insurance catalog, focus on monitoring catalog, hospital procurement catalog, but also pay attention to the hospital's cancer drug supply catalog.
anti-tumor drugs, once classified as restricted use, will have an inevitable impact on their market.
hundreds of billions of drugs market, the impact of malignant tumors is one of the most serious threats to human health and social development of the disease.
it is understood that in 184 countries and regions, China's incidence of malignant tumors in general is in the upper-middle level, accounting for about 21.8% of the global incidence of malignant tumors.
China's market for anti-tumor and immunomodulatory drugs reached 149.03 billion yuan in 2019, up 14.55 percent year-on-year, with huge market development prospects and potential, according to Minet.com.
(data source: minnet) by segment, the market share of anti-tumor drugs is the highest, at 64.43%, followed by immunostimulants 16.64%, endocrine therapy drugs 9.84%, and immunosuppressants 9.09%.
(data source: monenet) in anti-tumor drugs, the current international clinical common anti-tumor drugs about 80 kinds.
, the most used in our clinical is protein kinase inhibitors, the market share reached 21.22%, followed by anti-metabolic drugs 19.34%, monoclonal antibodies 18.93%.
(data source: Minnet Net) is due to market demand and market size, under strict supervision, the original market competition pattern will face inevitable impact.
In accordance with the requirements of the Measures, medical institutions shall, in accordance with the requirements of the Measures, give warnings to physicians who have ever had an extraordinary prescription more than 3 times and have no valid reasons to limit their prescribing rights;
medical institution shall cancel the right to prescribe if one of the following circumstances occurs: (1) to be ordered to suspend practice; (2) to be ordered to suspend his practice during the training period for failing to leave his post; (3) to cancel or revoke his practising certificate; (4) if he fails to prescribe an anti-tumor drug prescription, resulting in serious consequences; and (6) if he fails to prescribe an anti-tumor drug prescription for improper benefit.
it is clear that for pharmaceutical companies, not only by the hospital's cancer drug supply catalog, anti-tumor drug classification, but also will receive the impact of changes in the behavior of doctors' prescriptions.
some of the original non-compliance phenomena, are not allowed to happen again.
With the national clinical application of anti-tumor drugs to implement hierarchical management, those safer, accessible, more economical drugs, will usher in more market opportunities.
and those drugs toxic side effects, including toxic drugs management, strict adaptation, taboo evidence, expensive, heavy financial burden of drugs, will face more serious challenges.
.